8-K: Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings finalizes its merger with Cyclo Therapeutics, issuing shares and warrants, and focusing on the TransportNPC trial for Niemann-Pick Disease Type C1.

Summary

• Cyclo Therapeutics, Inc. has merged with Rafael Holdings, Inc. on March 25, 2025.
• Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics shareholders, representing approximately 22% of the combined company.
• The exchange ratio was determined to be 0.3525.
• Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants.
• Cyclo Therapeutics' shares and warrants will be delisted from the Nasdaq.
• The key asset is Trappsol Cyclo, currently in a Phase 3 clinical trial for Niemann-Pick Disease Type C1 (NPC1).
• Interim analysis results from the TransportNPC trial are expected in the middle of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of the merger and the focus on a promising clinical asset. However, there are inherent risks associated with clinical trials and regulatory approvals.

Positives

• The merger provides Cyclo Therapeutics with increased resources to advance its clinical programs.
• Rafael Holdings has identified Trappsol Cyclo as its lead clinical asset.
• The TransportNPC Phase 3 clinical trial is fully enrolled, indicating strong progress in the development of Trappsol Cyclo.
• The merger solidifies the commitment to deliver the results of the TransportNPC trial for shareholders and patients.

Negatives

• Cyclo Therapeutics' shares and warrants will be delisted from the Nasdaq, which may reduce liquidity for some investors.
• Former Cyclo Therapeutics directors and executive officers ceased serving in their capacities.

Risks

• The success of the merger depends on the successful development and commercialization of Trappsol Cyclo.
• Clinical trial results are uncertain, and the interim analysis may not be positive.
• The company faces risks related to regulatory approvals and market acceptance of Trappsol Cyclo.
• Forward-looking statements are subject to risks and uncertainties, as detailed in the company's filings with the SEC.

Future Outlook

Rafael Holdings will focus on developing clinical-stage assets, with Trappsol Cyclo as the lead candidate, and anticipates the interim analysis results from the TransportNPC trial in the middle of 2025.

Management Comments

• Bill Conkling, President and CEO of Rafael Holdings, stated that the merger is a major step forward in their strategy to develop clinical-stage assets in areas of high unmet medical need.
• Bill Conkling added that they are impressed with the execution of the team in fully enrolling a comprehensive clinical trial in NPC and eagerly await the interim analysis in the middle of 2025.
• N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, commented that the merger solidifies their commitment to deliver the results of the TransportNPC trial for shareholders and patients.

Industry Context

This merger reflects a trend in the biotechnology industry where smaller companies with promising clinical assets are acquired by larger companies with more resources to advance development and commercialization.

Comparison to Industry Standards

• The exchange ratio of 0.3525 is within the typical range observed in similar biotech mergers, reflecting the relative valuations of the two companies.
• The focus on a Phase 3 asset (Trappsol Cyclo) is consistent with industry trends, as larger companies often seek to acquire companies with assets that are closer to market.
• Comparable companies that have been involved in similar mergers include Actelion (acquired by Johnson & Johnson) and Genzyme (acquired by Sanofi).

Management Changes

Stakeholder Impact

• Shareholders of Cyclo Therapeutics received shares of Rafael Holdings, impacting their ownership and investment.
• Patients with Niemann-Pick Disease Type C1 may benefit from the continued development of Trappsol Cyclo.
• Employees of Cyclo Therapeutics are now part of Rafael Holdings, potentially impacting their roles and opportunities.

Next Steps

• Rafael Holdings will focus on the development of Trappsol Cyclo.
• The company will await the interim analysis results from the TransportNPC trial in the middle of 2025.
• The company will work towards regulatory approvals for Trappsol Cyclo.

Key Dates

Keywords

Merger, Cyclo Therapeutics, Rafael Holdings, Trappsol Cyclo, Niemann-Pick Disease Type C1, TransportNPC, Clinical Trial, Acquisition